Perrigo Company plc (PRGO) has settled Hatch-Waxman litigation relating to Picato (ingenol mebutate) gel, 0.015 percent, 0.05 percent brought by LEO Pharma Inc., LEO Pharma A/S, and LEO Laboratories Limited. Picato gel is indicated for the treatment of actinic keratosis. Perrigo Executive Vice President and President Rx Pharmaceuticals John Wesolowski stated, “This settlement is another example…

Perrigo Company’s Board of Directors approved a plan to separate the Company’s Prescription Pharmaceuticals (Rx) business following the Company’s previously announced strategic portfolio review. Continuing its focus on enhancing shareholder value, the Board believes a separation of the Rx business will better enable this unique asset to capitalize on its platform of differentiated generic pharmaceutical…